Tectonic Therapeutic Inc (NASDAQ: TECT) is a biotechnology company developing novel GPCR-targeted therapies for rare and chronic diseases. Using structure-based drug design and proprietary platform technology, it aims to unlock previously undruggable receptors. Tectonic’s shares move with clinical milestones, licensing partnerships, and progress advancing its pipeline of precision therapeutics.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
14:16, 11 3月 2026


